• 목록

Radiopharmaceuticals Development Lab, RDL

- Chemistry -

02  Research

A. Nanoparticle agents

 i. Practical development of nanoparticle for clinical use by enhancement of hydrophilicity and introduction of multi-functional groups using amphiphile encapsulation method.

 ii. Development of multimodal imaging agents for PET-MRI or PET-fluorescence.

B. Tumor imaging agents

 i. Development of nitroimidazole derivatives for hypoxia imaging.

 ii. Development of PSMA target tumor imaging agents for prostate cancer.

 iii. Development of amino acid derivatives. 

C. Brain imaging agents

 i. Development of brain receptor imaging agents: mGluR, benzodiazepine(GABA) receptor.

 ii. Development of serotonergic and dopaminergic system imaging agents.

 iii. Development of brain perfusion imaging agents.

 iv. Development of beta-amyloid plaque imaging agents: benzylideneaniline and benzothiophene.

D. Etc. 

 i. Radiolabeling methodology 

 i. Development of glomerular filtration imaging agents. 

 ii. Development of albumin based radiopharmceuticals for lymphoscintigraphy or atherosclerosis imaging: LSA, MSA.

iv. Development of therapeutic radiopharmaceuticals: Re-188, Lu-177, Y-90, I-131 etc.